ACTRN12624000816550尚未招募2 期
Feasibility Study of the Effect of Psilocybin in Response to Brief Psychological Input with Psychological Flexibility as a Mediating Factor on adults with Mild to Moderate Depression or Anxiety.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Capable of understanding and signing an informed consent form.
- •2.Aged 18 years and over on the day of consent.
- •3.Psychiatric history: Clinical interviews and assessments by referral agent – psychologists at student health/community mental health teams/private clinics
- •4.Participants with anxiety: Baseline scores of moderate to severe anxiety according to DASS-21 criteria and clinical assessment from referral agent (psychologist)
- •5.Participants with depression: Baseline scores of moderate to severe depression according to DASS-21 criteria and clinical assessment from referral agent (psychologist)
排除标准
- •1.Female Participants who are or intend to become pregnant, or are lactating.
- •2.Participants who, in the opinion of the investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
- •3.Any participant for whom the investigator believes, for any reason, that participation would not be an acceptable risk.
- •4.Participants with cardiovascular conditions
- •5.Current use of MAOIs, thyroxine or stimulants (amphetamine/methylphenidate). Use of antidepressants or other anxiolytics at stable doses > 4 weeks is acceptable.
- •6.Participants with severe acute or chronic medical illnesses.
- •7.Participants with a history of schizophrenia, psychosis, bipolar disorder, borderline personality disorder, and seizure disorders
- •6.Participants with current active suicidal ideation.
- •7.Substance abuse disorder, current or within the last 6 months.
研究者
相似试验
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-CZCOMPASS Pathfinder, Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-IECOMPASS Pathfinder, Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioEUCTR2017-003288-36-PTCOMPASS Pathfinder Limited216
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioTreatment-Resistant Depression (P-TRD)MedDRA version: 21.1Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10025463Term: Major depressive disorder, single episodeSystem Organ Class: 100000004873EUCTR2017-003288-36-DECOMPASS Pathfinder, Limited398
进行中（未招募）
1 期
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant DepressioEUCTR2017-003288-36-GBCOMPASS Pathways, Ltd216